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Glossary of Abbreviations 35 
CPB – cardio-pulmonary bypass 36 
CHD – congenital heart disease 37 
CHS – congenital heart surgery 38 
cTns – cardiac troponins 39 
ECMO - extracorporeal membrane oxygenation 40 
ICU – intensive care unit 41 
ILOS – intensive care length of stay 42 
IQR - inter-quartile range;  43 
miR-1 – microRNA-1 44 
miRNA - microRNA 45 
NHS – national health system 46 
PICU – pediatric intensive care unit 47 
RACHS-1 - risk adjustment for CHS 48 
SCE – severe cardiovascular event 49 
VI – ventilation index 50 
VIS – vasoactive-inotrope score  51 
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Central picture legend 52 
MicroRNAs could help predicting outcomes after pediatric congenital heart surgery.  53 
Central message 54 
MiR-1 increases in plasma after pediatric cardiac surgery. It is associated with clinical scores 55 
indicative of post-operative outcome and predicts intensive care stay and severe cardiovascular 56 
events.    57 
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Perspective statement 58 
miR-1 is a potential biomarker of cardiac outcomes after pediatric cardiac surgery, a field where 59 
accurate predictors are lacking. As opposed to the VIS and VI scores, changes in miR-1 appear 60 




Objective: Pediatric congenital heart surgery (CHS) involves intra-cardiac, valvular and vascular 63 
repairs. Accurate tools to aid short-term outcome prediction in pediatric CHS are lacking. Clinical 64 
scores, such as the vasoactive-inotrope score (VIS) and ventilation index (VI), are used to define 65 
outcome in clinical studies. MicroRNA-1-3p (miR-1) is expressed by both cardiomyocytes and 66 
vascular cells and is regulated by hypoxia. In adult patients, miR-1 increases in the circulation 67 
after open-heart cardiac surgery, suggesting its potential as a clinical biomarker. Thus, we 68 
investigated whether perioperative circulating miR-1 measurements can help predict post-CHS 69 
short-term outcomes in pediatric patients.   70 
Methods: Plasma miR-1 was retrospectively measured in a cohort of 199 consecutive pediatric 71 
CHS patients (median age 1.2 years). Samples were taken before surgery and at the end of the 72 
operation. Plasma miR-1 concentration was measured by RT-qPCR and expressed as miR-1 73 
copies/µl and as relative expression to spiked-in exogenous cel-miR-39.  74 
Results: Baseline plasma miR-1 did not vary across different diagnoses, increased during surgery 75 
(204-fold median relative increase, p<0.001) and was associated with aortic cross clamp duration 76 
post-operatively (p<0.001).  Importantly, miR-1 levels at the end of the operation positively 77 
correlated with intensive care stay (p<0.001), early severe cardiovascular events (p=0.01), and 78 
with high VIS (p=0.001) and VI (p<0.001), suggesting that miR-1 could accelerate the 79 
identification of patients with cardiopulmonary bypass-related ischemic complications, requiring 80 
more intensive support.  81 
Conclusions: Our study suggests miR-1 as a novel potential circulating biomarker to predict 82 
early post-operative outcome and inform clinical management in pediatric heart surgery. 83 
Abstract word count: 245 84 
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Introduction  85 
Congenital heart disease (CHD) affects around 1% of live births.1 Surgical results in CHD continue 86 
to improve, with varying mortality and morbidity based on case complexity.2 Infants undergoing 87 
congenital heart surgery (CHS) with cardiopulmonary-bypass (CPB) are at particularly high risk 88 
for postoperative morbidity and mortality,3 and few accurate predictors of outcomes are currently 89 
available beyond clinicians’ expert judgment. 90 
MicroRNAs (miRNA, miR) are short, non-coding ribonucleic acid molecules with multiple roles 91 
in regulation of cardiovascular developmental and pathological processes, including CHD.4 92 
miRNAs are released by cells via modalities, such as conjugation to lipoproteins or inclusion in 93 
extracellular vesicles, which improve their resistance to degradation while circulating in biological 94 
fluids. For this reason and for their relative cell and organ origin traceability, miRNAs are being 95 
considered as candidates for translation into clinical biomarkers.5 However, to the best of our 96 
knowledge, only one study of a small (n=30) CHS population has so far reported expressional 97 
changes in circulating miRs and it was developed on samples harvested at 12 hours after surgery, 98 
which does not allow for early perioperative prediction of post-surgical outcomes.6  99 
miR-1 is expressed prevalently by myocytes,7–9 but also by vascular cells and smooth muscle 100 
cells.10 Hypoxia modulates miR-1 expression,11,12 and studies have shown changes in circulating 101 
miR-1 in subjects suffering an acute myocardial infarction and in adult patients receiving open-102 
heart surgery and heart failure patients.9,13–17 We have previously shown that coronary artery-103 
bypass-graft (CABG) performed on CPB dramatically increases miR-1 trafficking from the adult 104 
human heart to the peripheral circulation and described the time-course of this phenomenon.18 105 
Others have showed miR-1 to be increased in the plasma after transcoronary ablation of septal 106 
hypertrophy.19 This would suggest a diagnostic potential of miR-1 in adult cardiac surgery, 107 
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however miR-1 has not been investigated in the CHS setting and correlated with post-surgical 108 
outcome.  109 
Currently, there are few predictors of post-operative outcomes in the pediatric intensive care unit 110 
(PICU), namely the vasoactive-inotrope score (VIS)3, measuring cardiovascular support; the 111 
ventilation index (VI), measuring ventilatory support20, and a composite score adding renal 112 
parameters to VIS and VI.21 These scores, predominantly used for research purposes, have shown 113 
good correlation with the PICU length of stay, but offer little insight into the causes underlying 114 
poor outcomes and are unable to inform treatment strategy3. Biomarkers such as cardiac troponins 115 
(cTns) and brain natriuretic peptides are routinely used, but early measurements after surgery 116 
require repeated sampling and can be unreliable.22,23 Therefore, there is a need for new biomarkers 117 
in pediatric CHS, where many complications are not due to pre-existing ischemic disease,  but are 118 
presumably secondary to the CPB. miR-1, given its cardiovascular expression and previously 119 
documented links to ischemic injury, appears to be a promising potential perioperative predictor 120 
of post-CHS outcome.  121 
 122 
Methods 123 
A detailed, expanded Methods section has been included in the Online Supplement. All patients 124 
were operated in the Bristol Royal Hospital for Children, using standardized cardiopulmonary 125 
bypass and myocardial protection, and received perioperative care as per local standard. Our 126 
cardioplegia is based on St Thomas’s solution and is mixed with blood in a 1:4 ratio. Maintenance 127 
doses are given every 20 minutes during mild hypothermic bypass and less frequently at 128 
hypothermia. 129 
Study protocol 130 
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DECISION (Detection of coagulopathy in pediatric heart surgery) is a prospective observational 131 
clinical study of coagulation biomarkers and bleeding outcomes in pediatric cardiac surgery, 132 
including intra-cardiac, valvular and vascular repairs for major congenital defects.24 Citrate plasma 133 
samples from blood were taken before the operation and at completion (before chest closure). 134 
Informed written parental consent was obtained for all participants for blood sampling and 135 
molecular biomarker analysis (Clinical study registration: ISRCTN55439761 (UK), National 136 
Research Ethics Service Committee reference: 13/LO/0504); all samples were obtained in 137 
accordance with the principles of the Declaration of Helsinki.  138 
The current study included the 205 consecutive children enrolled between May 2013 and March 139 
2015. Three patients did not consent for molecular biology analyses and 3 lacked complete clinical 140 
data, resulting in a final study group of 199 patients. All operations required CPB, but not all had 141 
aortic cross-clamping during CPB.  142 
Clinical, demographic, procedural and outcome data were collected from electronic patient files 143 
and PICU charts (Table 1).  Mean VIS values in the first 48 hours below the 25th percentile were 144 
defined as low, over the 75th percentile were defined as high, and those in between were defined 145 
as intermediate. We have chosen to use the mean VIS in the first 48 hours under the rationale that 146 
a continuous variable is useable in regression analysis, and it also captures both peak and prolonged 147 
support. A limitation of this metric is that it potentially has a lower predictive power. Both 148 
maximum VIS value in the first 48 hours3 and the point value at 48 hours25 can be used to isolate 149 
the “high VIS” group. When considering high VIS as an outcome in the logistical regression 150 
analysis, we used both the mean values above the 75th percentile and the high group as defined 151 
according to the maximum value,3 as the two approaches reflect a different pattern of 152 
cardiovascular support. Ventilation duration and ventilation index (VI)20,21 at 24 hours were 153 
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calculated to reflect the pulmonary impact; values were defined as high above the 75th percentile 154 
for both. Procedure complexity was classified using the risk adjustment for CHS (RACHS-1) 155 
score.26  156 
Cross-clamp times were classified as absent, short (under 25th percentile), intermediate (25th-75th 157 
percentiles) and long (over 75th percentile). Prolonged intensive care length of stay (ILOS) was 158 
defined as the duration of over the 75th percentile.  159 
Blood processing, RNA isolation, miRNA-1 measurement.  160 
Venous blood was collected from existing intravascular lines into a citrate tube and processed 161 
within 1 hour of collection. Aliquots of citrate plasma were stored at −80°C. In preparation for 162 
reverse transcription (RT)-qPCR analyses, total RNA was isolated from whole plasma using the 163 
Qiagen miRNeasy kit. To allow for normalization of sample-to-sample variation in the RNA 164 
isolation step27, the exogenous RNA oligonucleotide cel-miR-39 was spiked-in (5 fmol/10 μL) 165 
into each denatured sample. The RNA was eluted in RNase-free water and stored at −80°C. 166 
Because heparin reportedly inhibits both reverse transcriptase and polymerase and seems to be co-167 
purified with the RNA28, heparinase I treatment of RNA18,28,29 was carried out before RT, which 168 
was performed using TaqMan miRNA RT kit with miRNA-specific stem loop primers. Standard 169 
curves of chemically synthesized RNA oligonucleotides corresponding to miR-1 and cel-miR-39 170 
were created. The RT-qPCR reactions were carried out in duplicate. The raw Cts for miR-1 and 171 
cel-miR-39 were first normalized for inter-plate variability by calculating a normalization factor 172 
from the calibrator sample run along with the biological samples in each RT-qPCR experiment. 173 
Plasma expression of miR-1 was then analyzed in two ways: a) absolute quantification, i.e. plotting 174 
Ct values vs copies/µL of the synthetic miRNA in a standard curve obtaining miR-1 expression in 175 
copies/µL, b) relative expression to cel-miR-39 using the ΔΔCt method.  176 
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Statistical analyses 177 
Continuous variables are presented as median and interquartile range (IQR) as appropriate. Normal 178 
distribution of continuous variables was evaluated with the Shapiro-Wilk test. Wilcoxon paired-179 
samples test was used to compare pre- and post-operation miR-1 levels. Relative miR-1 increase 180 
is expressed as “n-fold”, where n is equal to post-operative miR-1 level divided by pre-operative 181 
miR-1 level. Differences in miR-1 concentrations and clinical parameters were tested with Mann-182 
Whitney U test or Kruskal-Wallis test, as appropriate, with Dunn’s test and Bonferroni adjustment 183 
for multiple testing if needed. Linear logistic regression with log transformation of non-normal 184 
variables and heteroskedasticity-robust standard errors was used to assess the relationship between 185 
pre-operative miR-1 values, post-operative miR-1 values, miR-1 increase, age, cross clamp 186 
duration and binomial outcomes based on: prolonged ILOS and severe cardiovascular events 187 
(SCE) defined as death in the ICU, cardiac arrest, need for extracorporeal membrane oxygenation 188 
or cardio-pulmonary resuscitation, high mean VIS, high maximum VIS, high ventilation duration, 189 
high VI. A p value <0.05 indicated statistical significance. Analyses were performed in STATA/IC 190 
11.2 (StataCorp LP, College Station, TX).  191 
 192 
Results  193 
Demographic and clinical data are reported in Table 1. The miR-1 values obtained from the two 194 
normalization methods correlated well, with R2=0.91 for pre-operative values (Supplemental 195 
Figure 1A) and 0.89 for post-operative values (Supplemental Figure 1B). Because of this very 196 
good correlation level, the miR-1 level expressed in copies/μL were used for the whole set of 197 
analyses.  198 
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No significant differences in baseline miR-1 were found with respect to gender or cardiac 199 
morphology in subgroups with over 10 patients each (subgroups with fewer than 10 patients were 200 
not included in the comparison) (data not shown). Average baseline miR-1 levels were 201 
significantly higher in infants when compared to children aged >1 year (1,249 vs 766 copies/µL, 202 
p<0.001). 203 
Plasma miR-1 increased dramatically during the operation, from a median of 992 (506-2,096) 204 
copies/µl at baseline to 224,277 (91,078-571,023) copies/µL (p<0.001) post-operatively, resulting 205 
in a median relative increase of 204 (89-489)-fold (Figure 1).  206 
Post-operative and perioperative increase in miR-1 inversely correlated with age at operation 207 
(coefficient -0.18 and -0.12 respectively, after log transformation; Supplemental Figures 2A and 208 
2B). Supplemental Table 1 shows the post-operative miR-1 levels and the relative miR-1 increase 209 
in patients receiving different surgical procedure types. The Fontan operation (rarely performed 210 
with cross-clamping), pulmonary valve replacements and subaortic stenosis relief (usually short 211 
cross-clamp times) were associated with both a lower miR-1 post-operative level and reduced miR-212 
1 perioperative changes. We did not find significant associations between post-operative miR-1 213 
levels and surgical complexity by RACHS-1 score (p=0.6). 214 
Median post-operative miR-1 level (Figure 2A) and miR-1 perioperative expressional changes 215 
(fold-increase, Supplemental Figure 3A) were higher in patients with longer cross-clamp (p<0.001 216 
for each comparison), with a linear correlation observed between miR-1 levels and cross-clamp 217 
duration (Figure 2B and fold-increase in Supplemental Figure 3B), suggesting that the miR-1 218 
release in the peripheral circulation was induced by myocardial or vascular ischemia rather than 219 
by the time the patient was connected to the CPB. Numerical values for post-operative miR-1 220 
levels and perioperative changes by cross-clamp duration are shown in Supplemental Table 2.  221 
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We found a correlation between muscular incision or resection and post-operative miR-1 levels 222 
(p<0.001). Moreover, muscular incision/resection correlated with the length of cross-clamping 223 
(p<0.001). Sensitivity analysis shows that the same trend seen in figures 2A and 2B is maintained 224 
when tested in subgroups with and without muscular incision/resection. We did not find significant 225 
associations between post-operative miR-1 levels and bypass temperature (p=0.3), pre-operative 226 
oxygen saturation <95% (p=0.1) or post-operative oxygen saturation <95% (p=0.6). We did find 227 
significantly higher postoperative miR-1 levels in patients with abnormal preoperative saturation 228 
versus normal saturation, but only in the subgroup with long cross-clamp duration (194,292 miR-229 
1 copies/nL vs 544,682 miR-1 copies/nL, p=0.01). We did not observe higher values in those with 230 
postoperative cyanosis, either by relation to the oxygen saturation or surgical procedure (e.g. shunt, 231 
pulmonary artery band). No correlation was found between postoperative miR-1 and the need for 232 
circulatory arrest (p=0.6) or overall duration of CPB (p=0.7, Supplemental Table 3). Median post-233 
operative miR-1 was higher in those patients with prolonged ILOS (Figure 3A) and with post-234 
operative severe cardiovascular events (SCE, Figure 3B). The miR-1 post-operative increase from 235 
baseline was higher in patients with prolonged ILOS (Supplemental Figure 4A) but not in those 236 
with SCE (Supplemental Figure 4B). There were 4 deaths; two neonates and two infants. Two had 237 
single ventricle physiology, one had AVSD-ToF and one had common arterial trunk. Three of 238 
them had urgent interventions and all four cases were complicated by postoperative organ failure. 239 
Patients with similar diagnoses and complications were also found among those who did not die. 240 
We finally analyzed how miR-1 compares with current predictors of acute outcome in pediatric 241 
congenital heart surgery, to address whether perioperative miR-1 measurements can accelerate the 242 
prediction of outcome, informing patient care. Median post-operative miR-1 was higher in patients 243 
with high and intermediate VIS compared to low VIS (Figure 4A). Moreover, post-operative miR-244 
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1 was higher in the high VI group compared to the intermediate and low VI groups (Figure 4B). 245 
In line with that, the perioperative changes in circulating miR-1 were higher in patients with high 246 
and intermediate VIS and high VI in comparisons with the other groups (Supplemental Figure 4C 247 
and 4D). Table 2 reports the numerical values detailing changes in miR-1 by ILOS and SCE groups 248 
and by VIS and VI groups. 249 
Details on univariable and multivariable analyses are presented in Table 3. In brief, in univariable 250 
analyses, post-operative miR-1, relative miR-1 increase, age and cross-clamp duration were all 251 
predictors of prolonged ILOS, VIS and VI. Only post-operative miR-1 and cross-clamp duration 252 
were predictors of severe cardiovascular events. In multivariable analysis only age and cross-253 
clamp duration were associated with prolonged ILOS, VIS and VI. We had only 8 SCE events, 254 
therefore, we could not perform multivariable analysis for SCE. 255 
 256 
Discussion 257 
This study measured miR-1 levels in 199 pediatric patients undergoing CHS and correlated miR-258 
1 to post-CHS outcomes. A dramatic increase in circulating miR-1 was observed immediately after 259 
CHS, when patients are still in the operating theatre, with higher post-operative miR-1 values in 260 
patients with prolonged cross-clamp times. Perioperative changes in miR-1 positively correlate 261 
with PICU length-of-stay and the post-operative occurrence of severe cardiac events. Circulating 262 
miR-1 levels at the end of the operation correlated with the VIS and VI, further suggesting the 263 
potential of miR-1 to be developed into a novel, minimally invasive laboratory biomarker suitable 264 
for early prediction of post-CHS complications related to ischemia due to CPB, if validated in 265 
further ad hoc designed studies, aiding in risk stratification and targeting interventions 266 
immediately after CHS completion. The value of miRs as peri-operative predictive biomarkers to 267 
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guide clinical management of surgical patients would require a rapid turnaround of laboratory 268 
results. Recent advances in molecular biology techniques show much promise in obtaining faster 269 
miRNA results, which is vital for clinical translation. In addition to digital PCR, an established 270 
technique known to be highly accurate, further simplifications of the traditional RT-qPCR 271 
approach abound, obviating the need for laborious RNA purification, reverse transcription and 272 
even PCR amplification itself. Alternative techniques such as flow cytometry are also showing 273 
promising development.30–32 The identification of the value of miRs as early prognostic biomarkers 274 
after surgical interventions could attract investment, further fueling the progression of 275 
technological advancements to obtain very fast results for miR expression analysis. CPB-related 276 
ischemic injury is an important cause of intensive care unit deaths and severe complications in 277 
pediatric cardiac surgery, with reduction of CPB ischemic times being advised.22 Thus, identifying 278 
potential markers and new pathogenic pathways could lead to better post-operative outcome 279 
through identifying patients at risk. Circulating miR-1 was higher after procedures requiring cross-280 
clamping of the aorta and it correlated with cross-clamp duration and age at operation, but not with 281 
total CPB duration or the need for circulatory arrest. This suggests that plasma miR-1 could 282 
increase as a result of either myocardial ischemia or ischemia/reperfusion injury (which is itself 283 
dependent on the ischemic time).33    284 
In patients undergoing ventriculotomy, the higher circulating level of miR-1 could derive from 285 
additional release from myocytes affected by the incision, but could also be a simple reflection of 286 
higher miR-1 release from the overall myocardium affected by ischemia/reperfusion response due 287 
to increased cross-clamp time, as indicated by ad hoc sensitivity analyses. This is of relevance 288 
because CPB can damage the heart not only via inflicting hypoxia/reoxygenation stress to the 289 
cardiomyocytes, but also by eliciting inflammatory responses.34 Indeed, one of the strengths of our 290 
16 
 
study is that patients undergoing various CHS procedures were included, allowing a comparison 291 
between subgroups based on cross-clamping length, including a group of patients not requiring 292 
cross-clamping. We propose that a circulating biomarker that can be of use in a variety of 293 
procedures has a significant potential to be adopted into clinical practice. Therefore, the correlation 294 
between miR-1 and clinical outcome observed in a diversity of operations increases our confidence 295 
that miRNA biomarkers could progress to clinical translation in CHS. Cross-clamp time itself 296 
provides a prognostic indication that is of value for the clinical team. Nonetheless, a laboratory 297 
biomarker enabling summing up of the information derived from considering multiple clinical 298 
parameters could significantly simplify evidence-based medical decisions, offering advantages in 299 
terms of precision and ease of standardization. Additionally, miR-1 is very highly enriched in 300 
cardiac muscle, while it is undetectable in platelets35 and is dramatically reduced in blood cells 301 
following myocardial ischemia.36 Taken together, the above suggest that circulating miR-1 302 
increases independently of inflammatory responses to surgery. Therefore, post-operative miR-1 303 
levels could exquisitely indicate the level of myocardial injury and the possibility for post-304 
operative severe cardiovascular events. Due to the limited number of SCE in our study population, 305 
we could not determine if miR-1 was an independent predictor for cardiac events. Nonetheless, we 306 
found post-operative miR-1 significantly increased in the SCE cases.  307 
Early neonatal mortality after CHS is still significant (5-10%).22 Laboratory-based biomarkers 308 
could improve both clinical care and clinical research in the CHS setting. Pediatric intensive care 309 
practitioners have developed “inotropic scores” to identify and quantify clinical factors from the 310 
early post-operative period indicative of illness severity and short-term outcome. However, 311 
inotropic scores present limitations: selection and titration of inotropic support is largely driven by 312 
institutional and even individual experience and practice algorithms22; VIS is calculated in the first 313 
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24-48 hours from arrival to PICU, which is quite a long period of time in the acute post-operative 314 
setting, and inotropic scores do little to discern whether the poor outcome is cardiac or extra-315 
cardiac in nature. Consequently, although possibly the best currently available predictor, VIS is 316 
difficult to translate into a biomarker able to assist clinical management. Other biomarker 317 
candidates, such as cTns and brain natriuretic peptides have been associated with early post-CHS 318 
outcomes 24 hours after surgery completion. Early cTn increase is common, but it is better 319 
associated with surgical gestures, especially intraoperative myocardial incisions, rather than with 320 
future complications. Additionally, sustained high values in repeated measurements are required 321 
to offer any clinical insight. Moreover, circulating levels of cTns after CHS can be affected by the 322 
anesthetic regimen, thus complicating the interpretation of laboratory results.37 An additional issue 323 
in using cTns to predict outcome in CHS relates to the fact that some CHD cases have significant 324 
circulating level of anti-troponin auto-antibodies already before surgery.38 Indeed, autoantibodies 325 
vs cTns have been shown to interfere with cTn detection.39  326 
The physio-pathological roles of miR-1, particularly in ischemic cardiovascular disease are only 327 
partly known.11,12,15,18 It is possible that the early circulating changes in miR-1 observed after CHS 328 
are associated with increased release of miR-1 from the producing cells. This could impact on the 329 
gene expression and hence the biology of the parent cells, but also on potential recipient cells at 330 
neighboring or more distant sites. Should this be the case, miR-1 could represent a functional 331 
biomarker and a potential therapeutic target alike. As is the case with any new potential biomarker, 332 
further research is required to confirm the value and precise role of miR-1 in practice. At the level 333 
of clinical research, miR-1 could be useful to assess novel myocardial protection and perfusion 334 
strategies. This could indirectly reflect in improving the clinical practice. This will have to be 335 




This is a retrospective study and the original prospective observational clinical study protocol did 338 
not include the direct measurement of post-operative cardiac function, such as by 339 
echocardiography, the collection of serial blood samples and measurement of cTn. Consequently, 340 
we were prevented from studying late post-operative dynamics of circulating miR-1 and 341 
correlating miR-1 levels with functional cardiac endpoints or an established cardiac injury marker. 342 
However, we would not expect cTns to be elevated at the very early post-operative time point 343 
analyzed here. Additionally, the mechanism for organ failure can be multifactorial and lead to poor 344 
correlation with just one biological marker.  345 
Both ventilation and vasoactive-inotropic support are dependent on clinical state and clinical 346 
decision at that time, resulting in significant expected variability not directly related to actual 347 
myocardial, vascular or pulmonary injury.  348 
The study group was not large enough to use multivariate analyses to validate the correlation 349 
between circulating miR-1 and significant cardiac adverse events. The data observed here require 350 
further validation in different CHS cohorts. We have not measured additional cardiovascular-351 
enriched miRs, which, when combined with miR-1, could improve the predictive value.  352 
Conclusions 353 
Translational research in the cardiac surgery setting is still under-developed.40 This is particularly 354 
true in pediatric CHS, due to intrinsic difficulties linked to patient consent and to the limited 355 
amount of blood and tissue that can be sampled. Investigations into minimally invasive circulating 356 
molecular biomarkers measurable in small volumes of biological fluids through standardized 357 
protocols are of utmost importance. We have provided the first evidence that miR-1 could serve 358 
as a novel circulating biomarker and is linked to cardiopulmonary bypass-related injury. The 359 
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correlation of miR-1 with the need for more cardiac and circulatory support, longer and more 360 
intensive ventilation and severe cardiovascular events after pediatric open-heart surgery 361 
demonstrates it has the potential to become a new biomarker in the early post-operative period.   362 
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Figure 3 494 
 495 
Figure 4 496 
 497 
Figure legends 498 
Figure 1. Box plot showing pre-operative and post-operative miR-1 levels (copies/µL) after 499 
congenital heart surgery. Plasma miR-1 median relative increase of 204 fold.  Log transformation 500 
was used to allow for large differences to be showed graphically. ***p<0.001 (n=199), Wilcoxon 501 
matched pairs test. Middle line represents the median value. The upper and lower borders of the 502 
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box represent the 75th and 25th percentiles, respectively. The upper and lower whiskers represent 503 
the maximum and minimum values of non-outliers. Outliers not shown.   504 
 505 
Figure 2. A. Box plot showing the post-operative miR-1 (copies/nL) by cross-clamp duration after 506 
congenital heart surgery. Patients with long (>92 min) and intermediate (45-92 min) cross-clamp 507 
duration had higher post-operative miR-1 levels when compared to low duration (<45 min) and 508 
absent cross-clamp.***p<0.001 vs no cross-clamp, ###p<0.001 vs short cross-clamp, p=0.1 for 509 
comparison between short cross-clamp vs no cross-clamp, Kruskal-Wallis test with Dunn post hoc 510 
test. Figure elements as described in figure 1 legend. B. Scatter plot with linear regression line 511 
showing the correlation between duration of cross-clamping and the post-operative miR-1 relative 512 
increase (vs baseline). 513 
 514 
Figure 3. A. Post-operative miR-1 (copies/nL) after congenital heart disease surgery in 199 515 
children, by intensive care length of stay (ILOS): prolonged ILOS (≥4 days) compared to short 516 
ILOS (<4 days). ***p<0.001, Dunn multiple comparison test with Bonferroni adjustment for 517 
multiple testing. B. Post-operative miR-1 (copies/nL) in patients with severe cardiovascular events 518 
(SCE, n=8) and those without SCE (n=191) during the intensive care stay. *p<0.05, Dunn multiple 519 
comparison test with Bonferroni adjustment for multiple testing. Figure elements as described in 520 
figure 1 legend.  521 
 522 
Figure 4. A. Post-operative miR-1 (copies/nL) after congenital heart disease surgery in 199 523 
children, by mean vasoactive inotrope score (VIS) group: low (<2.2), intermediate (2.2-6.7) and 524 
high (>6.7) mean VIS. ***p<0.001 vs low VIS, #p<0.05 vs intermediate VIS, Dunn multiple 525 
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comparison test with Bonferroni adjustment for multiple testing. B: Post-operative miR-1 526 
copies/nL by ventilator index (VI) group: low (<2.97), intermediate (2.97-9.85) and high (>9.85) 527 
VI. *p<0.05 and ***p<0.001 vs low VI; ##p <0.01 vs intermediate VI, Dunn multiple comparison 528 
test with Bonferroni adjustment for multiple testing. Figure elements as described in figure 1 529 
legend.  530 
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Age, years (median, IQR) 1.2 (0.4-5.7) 
Weight, kg (median, IQR) 8.5 (5.7-19.4) 
Male (n, %) 103 (51.8) 
Main diagnoses  
     Ventricular septal defect 40 (20.1) 
     Tetralogy of Fallot 31 (15.6) 
     Double outlet right ventricle 13 (6.5) 
     Atrioventricular septal defect – complete 12 (6) 
     Subaortic stenosis 12 (6) 
     Pulmonary atresia  11 (5.5) 
     Transposition with septal defect 10 (5) 
Non-cardiac comorbidities 88 (44.2) 
Main procedures  
     Ventricular septal defect closure 38 (19.1) 
     Tetralogy of Fallot repair 22 (11.6) 
     Pulmonary valve replacement 17 (8.5) 
     Fontan operation  14 (7.0) 
     Subaortic stenosis relief 12 (6.0) 
     Glenn operation  11 (5.5) 
     Atrioventricular septal defect complete repair 10 (5) 
32 
 
Redo operation (n, %) 89 (44.7) 
Operation complexity by RACHS-1 score (n, %)  
     1 (least complex) 7 (3.6) 
     2 128 (65.3) 
     3 42 (21.4) 
     4 15 (7.7) 
     5 0 (0) 
     6 (most complex) 4 (2.0) 
     Unclassifiable 3 (1.0) 
Pre-operative oxygen saturation <95% 68 (34) 
Bypass duration, min (median, IQR) 91 (68-122) 
Cross clamp used (n, %) 173 (86.9) 
Cross clamp time, min (median, IQR) 65 (45-92) 
Circulatory arrest needed 6 (3) 
Bypass temperature* 34 (32-35) 
Muscular incision/resection 64 (32) 
Intubation, hours (median, IQR) 16 (5-30) 
ILOS, days (median, IQR) 2 (1-4) 
Intubation time, hours (median, IQR) 16 (5-31) 
Mean 48 hours VIS (median, IQR) 3.8 (2.3-6.5) 
VI at 24 hours (median, IQR) 6.3 (2.7-9.8) 
Post-operative oxygen saturation <95% 16 (8) 
Cardiovascular event 8 (5.0) 
33 
 
     Death (n, %) 4 (2.0) 
     ECMO (n, %) 2 (1.0) 
     Resuscitated arrest (n, %) 4 (2.0) 
Dialysis (n, %) 14 (7.0) 
ECMO, extracorporeal membrane oxygenation; IQR, inter-quartile 
range; *due to anonymized data from a randomized trial, temperature 
data were missing in 90 patients (45%). 
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Table 2. Post-operative miR-1 absolute values and relative increase by mean 48 hours VIS, VI at 24 
hours and intensive care outcomes 





Mean 48 hours VIS     
     Low mean VIS 120.4 (31.6- 400.8) 
p<0.001 
106 (20-261) 
p=0.001      Intermediate mean VIS 204.6 (91.8- 568.1) 236 (116-504) 
     High mean VIS 349.6 (194.2- 740.8) 272 (136-479) 
VI at 24 hours 
     Low VI 112 (47.6- 276.7) 
p<0.001 
124 (27-204) 
p<0.001      Intermediate VI 209.1 (86.9- 602.3) 217 (98-503) 
     High VI 386.4 (203.5- 893) 312 (165-651) 
Prolonged ILOS     
    Yes 352.5 (174.6-825.7)  302 (158-568)  
    No  185.4 (54.8-424.2) p<0.001 171 (51-401) p=0.003 
Severe cardiovascular event 




     No (n=191) 211.2 (88-567.2) 201 (88-488) 
All values are presented as median (interquartile range). Shown are overall comparison p values from 




Table 3. Univariable and multivariable regression of predictors for pediatric intensive care outcomes  







High VI  Long ILOS Severe 
cardiovascular 
event 






OR p value OR p value OR p 
value 
OR p value 
Univariable 
analysis 






























<0.001 2.18 0.01 




























<0.001 1.02 0.01 
Multivariable 
analysis 




























































OR, odds ratio;  
Outcome was defined as VIS, ventilation length, VI or ILOS above the 75th percentile. 
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SUPPLEMENTAL MATERIAL 535 
 536 
Detailed methods 537 
Blood collection and plasma storage 538 
Venous blood was collected from existing intravascular lines into a citrate tube and processed 539 
within 1 hour of collection by centrifugation (1,300 g at 4°C) for 10 min. Plasma was aliquoted in 540 
RNase-free 1.5 mL tubes and stored at -80°C.   541 
RNA extraction and heparinase I treatment 542 
In preparation for RT-qPCR analyses, total RNA was isolated using the miRNeasy kit (Qiagen, 543 
Valencia, CA) according to the manufacturer’s recommendations for biological fluids. For RNA 544 
extraction from plasma, 0.5 mL of QIAzol was added to 100 µL of plasma or 100 µL purified EVs. 545 
To allow for normalization of sample-to-sample variation in the RNA isolation step,1 the synthetic 546 
RNA oligonucleotide cel-miR-39 (Qiagen, Valencia, CA), which is identical to the 547 
mature Caenorhabditis elegans miRNA cel-miR-39-3p, was spiked-in to each denatured sample 548 
at 10 μL (from a 5 fmol/μL stock). The RNA was eluted in 25 μL of RNase-free water and stored 549 
at −80°C. Heparin is known to inhibit both reverse transcriptase and polymerase2 and seems to be 550 
co-purified with the RNA. Heparinase I treatment of RNA preparations from plasma was therefore 551 
carried out before reverse transcription: 1.67 µL of purified RNA was transferred to a microtube 552 
containing 0.063 µL RNAse inhibitor, 0.5 µL 10X buffer and 0.075 µL Heparinase I (Sigma 553 
H2519, 0.02 U/µL)3 After incubation for 1 hour at room temperature, the solution was used without 554 
further treatment for the RT and qPCR reactions. We have shown previously that heparinase 555 
treatment does not affect results of miR PCR analyses in samples not contaminated by heparin.4 556 
Measurement of miRNA-1 in plasma by TaqMan RT-qPCR assays 557 
Reverse transcriptions reactions were performed using TaqMan miRNA reverse transcription kit 558 
with miRNA-specific stem loop primers (Life Technologies, Paisley, UK) in a small scale 5 µL 559 
RT reaction. For generation of standard curves of chemically synthesized RNA, oligonucleotides 560 
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corresponding to miRNA-1 and cel-miR-39 (Qiagen, Valencia, CA) were used; varying dilutions 561 
of each oligonucleotide were made in RNase free water such that the final input into the RT 562 
reaction had a volume of 1.67 µL. RT reactions were carried out on the thermocycler using the 563 
following conditions: 16°C for 30 min, 42°C for 30 min, 85°C for 5 min and then hold at 4°C.  564 
The RT-qPCR reactions were performed in duplicate in 10 µL reaction volumes using 0.5 µL of 565 
miRNA specific primer (Life Technologies, Paisley, UK), 5 µL of TaqMan gene expression master 566 
mix (Life Technologies, Paisley, UK), 3.84 µL nuclease-free H2O and 0.67 µL of RT product. The 567 
RT-qPCR reactions were carried out in duplicate using the following conditions: 95°C for 10 568 
minutes, followed by 95°C for 10 seconds, 60°C for 30 sec and optical read at 70°C for 1 second.  569 
The raw Cts for miR-1 and cel-miR-39 were first normalized for the inter-plate variability by 570 
calculating a normalization factor from the calibrator sample run along with the biological samples 571 
in each RT-qPCR experiment. Plasma miR-1 expression level were then calculated in two ways: 572 
by both absolute quantification, performed by plotting the Ct values vs copies/µL of the synthetic 573 
miRNA in a standard curve obtaining the miR-1 expression in copies/µL, and as relative 574 
expression to cel-miR-39, by using the ΔΔCt method.  575 
  576 
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Supplemental tables 577 
Supplemental Table 1. Post-operative (post-op) miR-1 level and relative 








   n=38 
389.7 (225.7- 855.1) 264 (127-761) 
Tetralogy of Fallot 
repair 
   n=22 
864.2 (480- 1886.1) 366 (260-819) 
Pulmonary valve 
replacement 
   n=17 
54.1 (23.7- 88.6) 96 (22-181) 
Fontan operation 
   n=14 
72.2 (40071- 92.6) 48 (17-142) 
Subaortic stenosis 
relief 
   n=12 
34.1 (16.2- 185.6) 67 (14-235) 
Glenn operation 
   n=11 




   n=10 
505.9 (304.8- 1113.1) 315 (165-798) 
Values are presented as median (interquartile range) 
Glenn operation and Fontan operation are 2nd and 3rd stages for single ventricle 
palliation 




Supplemental Table 2. Post-operative (Post-op) plasma miR-1 level (expressed as copies/nL) and 
miR-1 changes vs baseline by cross-clamp duration 
 Post-op miR-1 level 
(copies/nL) 








     Short cross-clamp <45 min  117.3 (31.7- 308.8) 122 (33-223) 
     Intermediate cross-clamp 
45-  92 min  
325.9 (134140- 813.3) 300 (129-636) 
     Long cross-clamp >92 min  424.2 (180.5- 721.3) 307 (162-671) 
 580 
 581 
  582 
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Supplemental Table 3. Multivariable regression model of post-operative 
(post-op) miR-1 level and relative increase in relation to age, cross-clamp and 
bypass duration 
Post-op miR-1 level  
 
Coefficient Robust SE p value 
Age  -0.17 0.02 <0.001 
Cross-clamp 
duration  0.01 0.003 <0.001 
Total bypass 
duration 0.001 0.002 0.7 
constant    11.99 0.2  
R-squared: 0.44 Root MSE: 1.08 
Post-op relative increase of miR-1 (ratio) 
 Coefficient Robust SE p value 
Age  -0.11 0.02 <0.001 
Cross-clamp 
duration  0.01 0.003 0.003 
Total bypass 
duration 0.002 0.003 0.46 
constant    4.71 0.24 
 
R-squared:0.27 Root MSE: 1.24 
 583 
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Supplemental Figure 1. Correlation of standardized (expressed as copies/nl) versus normalized 586 
(to cel-miR-39) values, showing very good linear correlations before (A) and after (B) surgery. 587 
Values exceeding the 95% percentile were not included in the figure to avoid clutter. Post-588 
operative normalized miR-1 values were significantly higher than the pre-operative values (median 589 
of 1.33 vs 0.004, p<0.001), with a median fold increase of 271 (103-591).   590 






Supplemental Figure 2. A. Scatter plot with linear regression line showing the inverse correlation 593 
between the post-operative miR-1 level (expressed as log transformed miR-1 copies/µL) and age. 594 
B. Scatter plot with linear regression line showing the inverse correlation between the miR-1 595 
relative increase and age. 596 






Supplemental Figure 3. A. Box plot graph showing post-operative relative miR-1 level increase 599 
by cross-clamp duration. Short (duration <45 min), Intermediate (45-92 min) and Long (>92 min) 600 
cross-clamp duration. P values are from Kruskal-Wallis with Dunn post hoc test, ***p<0.001 vs 601 
no cross-clamp, ###p<0.001 vs short cross-clamp, p=0.1 for comparison between short cross-clamp 602 
vs no cross-clamp. B. Scatter plot with linear regression line showing the correlation between the 603 
duration of the cross-clamping and the post-operative miR-1 relative increase (vs baseline). Middle 604 
line represents the median value. The upper and lower borders of the box represent the 75th and 605 
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25th percentiles, respectively. The upper and lower whiskers represent the maximum and 606 









Supplemental Figure 4. A. Box plot graph showing post-operative miR-1 relative increase by 612 
prolonged intensive care length of stay (ILOS). Short and Prolonged ILOS are <4 days and ≥4 613 
days, respectively. *p<0.05, Mann-Whitney U test. B. Box plot graph showing post-operative 614 
miR-1 relative increase in patients with severe cardiovascular events (SCE) during the intensive 615 
care stay (n=8) and those without (n=191). Mann-Whitney U test showed no significant difference. 616 
C. Box plot graph showing post-operative miR-1 relative increase in the 3 mean vasoactive-617 
inotrope score (VIS) groups: Low (<2.2), Intermediate (2.2-6.7) and High (>6.7) mean VIS. 618 
**p<0.01 vs low VIS, Kruskal-Wallis with Dunn post hoc test. D. Box plot graph showing post-619 
operative miR-1 relative increase in the 3 mean ventilation index (VI) groups:  Low (<2.97), 620 
Intermediate (2.97-9.85) and High (>9.85) VIS. *p<0.05 and ***p<0.001 vs low VI, Kruskal-621 
Wallis with Dunn post hoc test.  622 
Middle line represents the median value. The upper and lower borders of the box represent the 623 
75th and 25th percentiles, respectively. The upper and lower whiskers represent the maximum and 624 
minimum values of non-outliers. Outliers not shown. 625 
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